The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2015

Filed:

Jan. 21, 2014
Applicant:

Keith R Latham, Johnson City, TN (US);

Inventor:

Keith R Latham, Johnson City, TN (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/46 (2006.01); A61K 47/48 (2006.01); C07C 43/295 (2006.01); C07C 217/60 (2006.01); C07C 323/52 (2006.01); C07C 229/36 (2006.01); C07C 233/25 (2006.01); A61K 49/00 (2006.01); A61K 49/04 (2006.01); C07D 475/08 (2006.01); C07D 489/02 (2006.01); C07D 499/887 (2006.01); C07D 209/36 (2006.01); A61K 51/04 (2006.01); G01N 33/52 (2006.01); C07J 1/00 (2006.01); C07J 5/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48023 (2013.01); A61K 49/006 (2013.01); A61K 49/0438 (2013.01); A61K 51/0446 (2013.01); C07C 43/295 (2013.01); C07C 217/60 (2013.01); C07C 229/36 (2013.01); C07C 233/25 (2013.01); C07C 323/52 (2013.01); C07D 209/36 (2013.01); C07D 475/08 (2013.01); C07D 489/02 (2013.01); C07D 499/897 (2013.01); C07J 1/0022 (2013.01); C07J 5/0053 (2013.01); G01N 33/52 (2013.01); Y10T 436/145555 (2015.01);
Abstract

The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.


Find Patent Forward Citations

Loading…